Unlock instant, AI-driven research and patent intelligence for your innovation.

Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators

a technology of cycloalkylfused tetrahydroquinolines and receptors, which is applied in the field of cycloalkylfused tetrahydroquinolines, can solve the problems of limiting the dose that can be administered, affecting the safety of patients, and posing a number of systemic side effects

Inactive Publication Date: 2014-05-08
MERCK SHARP & DOHME CORP
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

This patent describes new compounds that can be used to treat diseases like asthma. These compounds target a specific protein called CRTH2. The invention also includes pharmaceutically acceptable salts or esters of the compounds. The technical effect is that these compounds can help control the symptoms of asthma and other related diseases by reducing the activity of CRTH2.

Problems solved by technology

The difficulty with treating patients with this class of compounds is that the compounds possess a number of systemic side-effects; these include adrenal suppression, altered bone metabolism and growth suppression in children.
These side effects limit the dose that can be administered on a daily basis to the patient.
While a non-steroidal class of therapeutics that inhibit bronchoconstriction exists (CysLT1 antagonists), this class of compounds has limited efficacy in achieving the endpoints of reducing inflammatory and improving in lung function when compared to the glucocorticoids.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
  • Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators
  • Cycloalkyl-fused tetrahydroquinolines as crth2 receptor modulators

Examples

Experimental program
Comparison scheme
Effect test

example 1

Preparation of Racemic Benzyl cis,cis-9-(cyclopropylamino)-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (1E)

Step 1: Benzyl 2-allyl-4-oxo-3,4-dihydroquinoline-1(2H)-carboxylate

[0443]

[0444]A solution of allylmagnesium bromide (1.00 M in tetrahydrofuran, 101 mL, 101 mmol, 2.00 equiv) was added to a solution of 4-methoxy quinoline (8.00 g, 50.3 mmol, 1 equiv) in tetrahydrofuran (335 mL) at −78° C. The reaction mixture was stirred at −78° C. for 1 h, then benzyl chloroformate (14.35 mL, 101.0 mmol, 2.00 equiv) was added via syringe over 5 min. The reaction mixture was stirred for an additional 15 minutes at −78° C., then the cooling bath was removed and the reaction mixture was allowed to warm to 23° C. After 1 h, added methanol (40 mL). After stirring for 5 min, aqueous hydrochloric acid solution (2 N, 20 mL) was added and the mixture was stirred for 10 min. The mixture was then concentrated by rotary evaporation to remove most of the tetrahydrofuran and methanol, and...

example 2

Preparation of Racemic Benzyl cis,cis-9-amino-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (2)

[0453]

[0454]Sodium cyanoborohydride (78 mg, 1.2 mmol, 2.0 equiv) was added to a mixture of benzyl cis-9-oxo-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (200 mg, 0.622 mmol, 1 equiv) and ammonium acetate (480 mg, 6.22 mmol, 10 equiv) in methanol (6.2 mL). The reaction vessel was sealed and heated to 70° C. After stirring at 70° C. for 90 min, the reaction mixture was cooled to 23° C. and partitioned between ethyl acetate and saturated aqueous sodium bicarbonate solution. The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated. The residue was purified by flash-column chromatography (50% ethyl acetate-hexanes, grading to ethyl acetate, then flushing with 10% methanol-dichloromethane) to afford 2.

example 3

Preparation of Racemic Benzyl cis,cis-9-(acetylamino)-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate (3)

[0455]

[0456]Acetic anhydride (0.250 mL, 2.65 mmol, 5.00 equiv) was added to a solution of benzyl cis,cis-9-amino-1,2,3,3a,9,9a-hexahydro-4H-cyclopenta[b]quinoline-4-carboxylate 2 (171 mg, 0.530 mmol, 1 equiv) and N,N-diisopropylethylamine (0.278 mL, 1.59 mmol, 3.00 equiv) in dioxane (5.3 mL) at 23° C. The reaction mixture was stirred for 10 min, and then was partitioned between ethyl acetate and aqueous hydrochloric acid solution (1 N). The organic layer was washed with saturated aqueous sodium chloride solution, and the washed solution was dried over sodium sulfate. The dried solution was filtered, and the filtrate was concentrated to afford 3. [M+H]+: 365.2.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

The invention provides certain cycloalkyl-fused tetrahydroquinolines of the Formula (I), and their pharmaceutically acceptable salts and esters, wherein R1, R2, R7, R8a, E, Y, Z, n, u, and t are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions associated with uncontrolled or inappropriate stimulation of CRTH2 function.

Description

FIELD OF THE INVENTION[0001]The present invention relates to certain cycloalkyl-fused tetrahydroquinolines of the Formula (I) (also referred to herein as the “compounds of the Formula (I)”), compositions comprising such compounds, and methods of using such compounds for treating an inflammatory disease, or other disorder mediated by the chemoattractant receptor-homologous molecule expressed on T-helper-type-2 cells (CRTH2).BACKGROUND OF THE INVENTION[0002]Prostaglandin D2 (PGD2) belongs to a class of chemical mediators which cells synthesize in response to stimuli, such as local tissue damage or hormonal stimuli, or by cellular activation pathways. Cells synthesize PGD2 from arachidonic acid by cyclooxygenase and other specific synthases in the pathway.[0003]Upon stimulation, mast cells release PGD2 in major amounts and this release plays a major role in the etiology of respiratory disease, such as asthma and congestion. PGD2 achieves this effect by binding with either of two G-prot...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): C07D221/16A61K31/5377C07D401/12A61K31/506A61K31/501A61K31/473C07D401/10
CPCC07D221/16A61K31/473A61K31/5377C07D401/10A61K31/506A61K31/501C07D401/12C07D401/04C07D401/06C07D405/06C07D405/12C07D413/04C07D413/12C07D417/12C07D409/12C07D417/10A61P11/00A61P11/02A61P11/06A61P29/00A61P37/08A61P43/00
Inventor HUANG, XIANHAIBRUBAKER, JASONPETERSON, SCOTT L.BUTCHER, JOHN W.CLOSE, JOSHUA T.MARTINEZ, MICHELLEMACCOSS, RACHEL NICOLAJUNG, JOON O.SILIPHAIVANH, PHIENGZHANG, HONGJUNASLANIAN, ROBERT G.BIJU, PURAKKATTLE JOHNYDONG, LIHUANG, YINGMCCORMICK, KEVIN D.PALANI, ANANDANSHAO, NINGZHOU, WEI
Owner MERCK SHARP & DOHME CORP